Active immunization against infections caused by all known subtypes of hepatitis B virus (HBV). The vaccine should also prevent hepatitis D. Groups of people who should be vaccinated because of the risk of hepatitis B infection are defined in the Protective Vaccine Program.
Composition:
1 dose for children (0.5 ml) contains 10 μg of recombinant virus surface antigen hepatitis B (HBsAg); 1 adult dose (1 ml) contains 20 μg of recombinant HBsAg.
Action:
Vaccine for active immunization against hepatitis B. Contains a surface antigen of the virus hepatitis Bobtained from yeast cell recombination and adsorbed on aluminum hydroxide. The HBs antigen induces an immune system response that stimulates specific antibodies and creates mechanisms of immune memory. The protective level of antibodies is obtained after primary vaccination (3 doses), which gives immunity for many years. The immunogenic properties of the vaccine are enhanced by the adjuvant action of aluminum hydroxide.
Contraindications:
Hypersensitivity to any of the components of the vaccine or the occurrence of symptoms of hypersensitivity after the previous dose of the vaccine. acute illnesses with fever - vaccinations should be postponed. Do not administer intravenously, subcutaneously and in the buttocks.
Precautions:
If vaccination is done during the incubation of the hepatitis B virus, it may not prevent the disease. The immune response may be reduced in men, people over the age of 40, obese, smokers, in patients on dialysis or with immunodeficiency; you may need additional doses of the vaccine in these patients.
Pregnancy and lactation:
During pregnancy and breastfeeding, use only in the case of a high risk of infection and when the benefits for the mother outweigh the potential risk to the fetus or the fed baby.
Side effects:
Very common: pain, erythema, hardening at the injection site. Uncommon: fatigue, malaise, flu-like symptoms, fever, diarrhea, headache and dizziness, pharyngitis, cough, rhinitis, erythematous rash, pruritus. Very rare: palpitations, abdominal pain, nausea, decreased appetite, muscle aches, joint pain, back pain, neck pain, decreased concentration, paresthesia, drowsiness, hypersensitivity reactions (rash, pruritus, urticaria, edema, angioneurotic edema, dyspnoea, bronchospasm ).
Dosage:
Intramuscularly (adults and older children in the deltoid muscle, newborns, infants and younger children - in the thigh muscle, exceptionally, in patients with blood coagulation disorders, the vaccine may be given subcutaneously). The dose of 20 μg / ml is intended for adults and children over 15 years of age; dose 10 μg / 0.5 ml - for newborns, infants and children up to 15 years of age. Primary vaccination (0,1,6 months): the first dose at the chosen date, the second dose 1 month later, the third dose 6 months after the first dose vaccination. In order to obtain immunity in a short time, three doses can be administered at intervals of one month, in this regimen a fourth dose is recommended 12 months after the first vaccination (0,1,2,12 months). For people at high risk, it is recommended to check the level of antibodies; if the antibody level is lower than 10 IU / L, booster immunization should be performed. If there is a risk of direct infection, the first dose should be administered as soon as possible together with immunoglobulin and then an accelerated vaccination schedule should be used.
(C)
